Literature DB >> 11720680

Radioguidance for nonpalpable primary lesions and sentinel lymph node(s).

R J Gray1, R Giuliano, E L Dauway, C E Cox, D S Reintgen.   

Abstract

BACKGROUND: Radioguided surgery can also be used for the simultaneous guidance to a nonpalpable primary tumor and sentinel lymph nodes.
METHODS: Retrospective review of a prospective database. The surgeon used a gamma probe for guidance to an iodine-125 labeled titanium seed at the primary lesion and technetium-99 labeled sulfur colloid at the sentinel lymph node.
RESULTS: Forty-three patients with nonpalpable breast carcinoma underwent dual isotope radioguided surgery. The radioactive seed and primary lesion were retrieved in the first excision in all 44 patients (100%). Eleven patients (25%) had pathologically involved margins. Sentinel lymph node mapping was successful in 42 patients (98%). A mean of 2.4 sentinel nodes were excised and metastatic carcinoma was present in four patients (10%).
CONCLUSIONS: Dual isotopes can be effectively used in breast cancer patients for simultaneous radioguidance to both a nonpalpable primary lesion and sentinel lymph node and allows for improved logistics.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11720680     DOI: 10.1016/s0002-9610(01)00716-4

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  2 in total

Review 1.  A comprehensive overview of radioguided surgery using gamma detection probe technology.

Authors:  Stephen P Povoski; Ryan L Neff; Cathy M Mojzisik; David M O'Malley; George H Hinkle; Nathan C Hall; Douglas A Murrey; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2009-01-27       Impact factor: 2.754

2.  A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions.

Authors:  Gabriele Caviglioli; Marco Chinol; Sara Baldassari; Lucia Garaboldi; Guendalina Zuccari; Andrea Petretto; Giuliana Drava; Chiara Sinico; Giovanni Paganelli
Journal:  Sci Rep       Date:  2019-04-04       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.